Syndesi Therapeutics

AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect
Fierce Biotech
Tue, 03/1/22 - 10:42 am
AbbVie
M&A
Neuroscience
Syndesi Therapeutics
UCB Pharma
Alzheimer's disease
depression